Felice, Carla
 Distribuzione geografica
Continente #
EU - Europa 993
NA - Nord America 936
AS - Asia 151
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 2.087
Nazione #
US - Stati Uniti d'America 930
DE - Germania 507
SE - Svezia 135
CN - Cina 104
UA - Ucraina 92
IT - Italia 68
FR - Francia 54
GB - Regno Unito 48
IE - Irlanda 35
IN - India 25
FI - Finlandia 24
BE - Belgio 9
TR - Turchia 9
CA - Canada 6
IR - Iran 6
RU - Federazione Russa 4
CI - Costa d'Avorio 3
JP - Giappone 3
NL - Olanda 3
PL - Polonia 3
BG - Bulgaria 2
CH - Svizzera 2
ES - Italia 2
GR - Grecia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
HU - Ungheria 1
IL - Israele 1
KR - Corea 1
MA - Marocco 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SG - Singapore 1
TW - Taiwan 1
Totale 2.087
Città #
Chandler 227
Ashburn 85
Jacksonville 79
San Mateo 50
Dearborn 47
Ann Arbor 38
New York 38
Nürnberg 37
Dublin 34
Cattolica 30
Nanjing 28
Wilmington 24
Milan 19
Munich 19
Bremen 17
Boston 15
Beijing 14
Lawrence 14
Houston 12
Lancaster 11
Brussels 9
Izmir 9
Princeton 9
Leawood 8
Nanchang 8
Detroit 7
Jiaxing 7
Redwood City 7
Seattle 7
Marseille 6
Mountain View 6
Shenyang 6
Changsha 5
Hebei 5
Helsinki 5
Woodbridge 5
Andover 4
Ardabil 4
Boardman 4
Fairfield 4
Hefei 4
Redmond 4
Shanghai 4
Tianjin 4
Abidjan 3
Augusta 3
Costa Mesa 3
Edinburgh 3
Kunming 3
Los Angeles 3
Simi Valley 3
Toronto 3
Washington 3
A Coruña 2
Amsterdam 2
Athens 2
Changchun 2
Fremont 2
Hangzhou 2
Jinan 2
Kish 2
Kraków 2
Millbury 2
Napoli 2
Norwalk 2
Pune 2
Raritan 2
Rome 2
Sofia 2
Tappahannock 2
University Park 2
Berlin 1
Bern 1
Bucharest 1
Budapest 1
Casablanca 1
Chengdu 1
Clearwater 1
Delhi 1
Frankfurt am Main 1
Fuzhou 1
Guangzhou 1
Henderson 1
Ipswich 1
Kyiv 1
Ladispoli 1
Landshut 1
Lanzhou 1
Lisbon 1
London 1
Moncalieri 1
Monmouth Junction 1
Montreal 1
Montréal 1
Mumbai 1
Ningbo 1
Novara 1
Ocean Grove 1
Paris 1
Phoenix 1
Totale 1.071
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 147
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 137
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 136
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 131
Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects. 130
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 130
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 127
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 113
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 108
Ileal Crohn's disease: CEUS determination of activity 98
Use of infliximab in particular clinical settings: management based on current evidence. 94
Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association 82
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 81
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 76
Management of perianal fistulas in Crohn's disease: an up-to-date review 69
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 69
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 66
AID in aging and autoimmune diseases 65
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 56
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 56
Biological therapies for inflammatory bowel disease: controversies and future options 45
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 45
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 34
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 6
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 4
Totale 2.105
Categoria #
all - tutte 6.158
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.158


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201946 0 0 0 0 0 0 0 0 0 0 34 12
2019/2020352 61 18 42 11 29 58 28 16 24 12 31 22
2020/2021178 5 20 3 23 23 4 16 9 24 2 40 9
2021/2022237 27 17 4 39 4 3 3 47 7 4 30 52
2022/2023528 71 73 33 103 33 63 17 40 68 2 15 10
2023/2024197 10 50 6 20 3 50 3 33 10 12 0 0
Totale 2.105